Recurrence Patterns, Treatment Outcomes, and Prognostic Factors of Thymic Carcinoma: A Multicenter Study
Authors:
- Natsuo TomitaNatsuo Tomita
- Shunichi IshiharaShunichi Ishihara
- Yoshihito NomotoYoshihito Nomoto
- Akinori TakadaAkinori Takada
- Katsumasa NakamuraKatsumasa Nakamura
- Kenta KonishiKenta Konishi
- Kohei WakabayashiKohei Wakabayashi
- Yukihiko OhshimaYukihiko Ohshima
- Maho YamadaMaho Yamada
- Masayuki MatsuoMasayuki Matsuo
- Masaya ItoMasaya Ito
- Katsuhiro OkudaKatsuhiro Okuda
Open Access
Abstract
Objectives: This multicenter study aimed to clarify the recurrence patterns; treatment outcomes; and prognostic factors of thymic carcinoma, a rare cancer. Methods: We analyzed 101 patients with thymic carcinoma who underwent multidisciplinary treatment, including radiotherapy. The median age was 62 years, with 27 patients in stage I–II; 44 in stage III; and 30 in stage IV by the TNM classification. Seventy-two patients underwent surgery with radiotherapy; and 29 patients underwent definitive radiotherapy. Image-guided radiotherapy (IGRT) and elective nodal irradiation (ENI) were used for 35 and 23 patients, respectively. Local recurrence-free survival (LRFS); progression-free survival (PFS); and overall survival (OS) were calculated, and univariate and multivariate analyses were performed. Results: With a median follow-up of 68 months, we observed 17 local recurrences; 27 regional recurrences; and 35 distant metastases. The 5-year LRFS; PFS; and OS were 82%, 41%, and 76%, respectively. Multivariate analysis revealed that stage was the only factor associated with LRFS; PFS; and OS (p = 0.040; p < 0.0001; and p = 0.048, respectively), while treatment modality was associated with only LRFS (p = 0.015). IGRT and ENI were also associated with LRFS (p = 0.002 and 0.013, respectively). PFS and OS of stage IV patients were comparable between the surgery with radiotherapy and definitive radiotherapy groups (p = 0.99 and 0.98, respectively). Conclusions: Our results suggest the importance of stage-specific treatment strategies rather than resectability, especially for stage IV patients. These results should be validated in a prospective study. Our results also suggest that radiotherapy methods influence recurrenceKeywords
Funding Information
- JSPS KAKENHI (25K11017)
This publication has 33 references indexed in Scilit:
- The International Association for the Study of Lung Cancer Thymic Epithelial Tumor Staging Project: Proposal for the T Component for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant TumorsJournal of Thoracic Oncology, 2023
- American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic CarcinomaJAMA Oncology, 2023
- The Role of Adjuvant Therapy in Advanced Thymic Carcinoma: A National Cancer Database AnalysisThe Annals of Thoracic Surgery, 2020
- Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic CarcinomaJournal of Thoracic Oncology, 2018
- The Impact of Postoperative Radiotherapy for Thymoma and Thymic CarcinomaJournal of Thoracic Oncology, 2017
- Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2017
- Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database StudyCancer, 2015
- Thymic carcinoma outcomes and prognosis: Results of an international analysisThe Journal of Thoracic and Cardiovascular Surgery, 2015
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- Follow-up study of thymomas with special reference to their clinical stagesCancer, 1981